UMMC Hits Enrollment Target for MK-4280A-010 Study

We are proud to celebrate yet another milestone achieved by the exceptional team at UMMC, led by Principal Investigator, Associate Prof. Dr. Wan Zamaniah, and her dedicated Study Coordinators, Ms. Suganiya Rama Rao and Ms. Ku Sheau Lee. The site has officially reached its enrollment target of 6 subjects, becoming the first site in Malaysia to achieve this remarkable feat on 7th November 2024!

Key Achievements to Date:

  • First site in Malaysia to enroll subjects for both Cohort A and Cohort B.
  • First site to meet the overall site target of 6/6 subjects.
  • Successfully enrolled 50% of Malaysia’s overall target for both cohorts in less than 6 months.
  • Achieved the site target within a year of study activation.

Recognizing Cohort B Success

On 3rd October 2024, the team also reached another milestone by completing the Cohort B target (4/4) well ahead of schedule—an extraordinary accomplishment, as enrollment for Cohort B was expected to continue through June 2025. This level of dedication and efficiency speaks volumes about the team’s commitment to advancing clinical research and improving treatment options for cutaneous squamous cell carcinoma (cSCC) and esophageal cancer (EC).

A Word of Thanks

We extend our heartfelt gratitude to the UMMC study team for their resilience and unwavering efforts. Despite the many challenges along the way, your steadfast commitment has driven these milestones and supported the larger goal of advancing healthcare in Malaysia.

Your willingness to increase the site’s target to assist in achieving the country’s overall goal demonstrates a true spirit of collaboration and teamwork.

Looking Forward

This is not just a significant milestone for the MK-4280A-010 study but also a testament to the dedication and excellence that the UMMC team consistently delivers. We’re excited for the milestones yet to come and are honored to continue this journey with such an incredible team.

UMMC’s incredible contributions to this study, including being the first site in Malaysia to achieve its enrollment target, underscore the pivotal role our local investigators and study teams play in advancing global cancer research.

Let’s keep the momentum going as we work together to improve patient outcomes and explore new frontiers in oncology research!

#ClinicalTrials #UMMC #ResearchMilestone #CICUMMC #MK4280A010 #OncologyResearch #MK4280A #Immunotherapy #CutaneousSCC #EsophagealCancer

Share:

More Posts

Newsletter

Scroll to Top